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THROMBOSIS AND HEMOSTASIS - PLATELETS
CO-057
LOW DOSE RITUXIMAB SHARES SIMILAR ACTIVITY BUT SLOWER TIMING OF RESPONSE
THAN STANDARD DOSE IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
Zaja F,1 Battista ML,1 Pirrota MT,2 Calmieri S,3 Montagna M,4 Marin L,1
Cavallin M,1 Bocchia M,2 Defina M,2 Ippoliti M,2 Ferrara F,3 Patriarca F,1
Avanzino MA,4 Ragazzi M,4 Fanin R1
1Clinica Ematologica, DIRM, Azienda Ospedaliera Universitaria, Udine; 2Clin-
ica Ematologica, Policlinico Le Scotte, Siena; 3Divisione di Ematologia, AORN
A. Cardarelli, Napoli; 4Dipartimento di Farmacologia, IRCCS-Policlinico San
Matteo, Pavia, Italy
Introduction. Rituximab 375 mg/sqm weekly for 4 weeks has significant
activity in patients with immune thrombocytopenia (ITP). In this setting,
different biological and clinical evidence suggests the possible use of
lower doses of Rituximab. Methods. Twenty-one adult patients, median
age 44 years (range 16-71 years), with previously treated and sympto-
matic ITP (18 idiopathic, 3 secondary) were treated prospectively with
Rituximab at the fixed dose of 100 mg iv weekly for 4 weeks. Exclusion
criteria were positive HIV, HBsAg and pregnancy test, any B-cell lym-
phoprolipherative disease, other malignancies. Response assessment
was evaluated considering the rate of complete and partial responses
(CR, PR; platelet level ≥100 and 50×109/L, respectively and discontinu-
ation of steroid therapy, if present), the time to response (TTR; time
necessary to reach a platelet number ≥50×109/L), the time to complete
response (TCR; time necessary to reach a platelet number ×109/L) and
the duration of response. Peripheral blood immunophenotypic analysis
of CD20 was evaluated at baseline and then monthly from the begin-
ning of treatment. B-cell count and pharmacokinetics (PK) were moni-
tored and related with clinical outcome. Results. All patients completed
the therapeutic program receiving the four infusions of Rituximab as
scheduled, none experiencing short term toxicity. All patients achieved
B-cell depletion, still maintained at follow-up. Overall, CR and PR rates
were 15/21 (71%), 10/21 (47%), 5/21 (24%). Younger age, lower base-
line circulating CD20 positive lymphocyte count and shorter diagnosis
to Rituximab interval were associated with higher response rate. The
median TTR and TCR were 30 and 50 days respectively, significantly
longer then those observed with standard dose in patients with similar
characteristics (Haematologica 2003;88:538). After a median follow-up
of 6 months (range 3-15), 6/15 patients relapsed, and 3 needed further
treatments. PK data showed a concentration time-course profile of Rit-
uximab that was super-imposable, once corrected for the difference in
the dose, to that observed previously in patients treated with standard
dose, diseases with a median value of 4.1 micrograms/milliliter (range
0-11.9), 12 weeks after the start of treatment. Discussion. In patients with
ITP, low dose Rituximab led to short and mid-term response rates sim-
ilar to standard dose but with slower timing of response. These results
highlight the need for a more specific therapeutic schedule of Ritux-
imab in autoimmune diseases.
CO-058
INCIDENCE AND DETERMINANTS OF BLEEDING IN VON WILLEBRAND DISEASE:
RESULTS OF THE FIRST PROSPECTIVE MULTICENTER STUDY ON 814 ITALIAN PATIENTS
Federici AB,1 Bucciarelli P,1 Castaman G,2 Mazzucconi MG,4 Morfini
M,6 Rocino A,5 Schiavoni M,3 Rodeghiero F,2 Mannucci PM,1 (On
behalf of the A.I.C.E., the Italian Association of Hemophilia Centers)
1Angelo Bianchi Bonomi Hemophilia Thrombosis Center, Department of Inter-
nal Medicine and Medical Specialties, I.R.C.C.S. Maggiore Policlinico Hospi-
tal, Mangiagalli, Regina Elena Foundation and University of Milan; 2Division
of Hematology, San Bortolo Hospital, Vicenza;3Hemophilia Thrombosis Center,
Ospedale Policlinico, Bari; 4Hemophilia Center, Department of Hematology,
University of Rome; 5Hemophilia Center, Pellegrini Hospital, Naples; 6Hemophil-
ia Center, Careggi Hospital, Florence, Italy
Background. von Willebrand disease (VWD) is the most frequent inher-
ited bleeding disorder and is due to quantitative and/or qualitative
defects of von Willebrand factor (VWF). Despite its improved knowledge
among hematologists, no data on the incidence and determinants of
bleedings requiring specific treatments are available until now. Aims and
design of the study. To determine the incidence and determinants of bleed-
ings requiring therapy with DDAVP and/or VWF concentrates in VWD,
a national registry was organized by using a database devised to collect
detailed retrospective information. Patients included in the registry were
followed up for one year and prospective data on number, type and
management of bleeding episodes was analyzed. Methods. All patients
were diagnosed following recommendations of the ISTH-SSC-SC on
VWF with bleeding severity score (BSS) calculated at enrollment. Diag-
noses of VWD were confirmed by the coordinating center using multi-
meric analysis in plasma and mutations of VWF gene in types 2 and 3.
For different risk categories the incidence of bleeding (mucosal and non-
mucosal bleeding) was calculated. Bleeding-free survival was comput-
ed with the Kaplan-Meier method and a Cox’s proportional hazard mod-
el was used to calculate the risk of bleeding in different risk categories.
(hazard ratio = HR). Results. In the retrospective study, 1,234/1,529 (81%)
cases satisfied the inclusion criteria and were enrolled in the registry as
types 1 (54%), 2 (40%) and 3 (6%).VWD diagnosis occurs in young
adults (83%), mainly in women (57%). Mucosal bleeding (64%) are is
more frequent than hematomas or hemarthrosis (15%) but 73% of
patients did not require transfusions. In the prospective study based on
814/1,234 (66%) cases of the registry (type 1=47%, 2=47%, 3=6%)
147/815 (18%) were treated in a year for 318 bleeding episodes and 87
minor or major surgeries. BSS >10 ([hazard ratio =6.8, (95%CI 3.8-12.3)],
bleeding time <20 min ([BT = 5.5, (3.1-9.8)], VWF:RCo <10 U/dL ([3.2,
(1.7-5.9)] and FVIII:C <20 U/dL ([4.1, (2.4-7.0)] were significantly asso-
ciated with high risk of bleeding. By multivariate model including all the
variables, BSS ([5.5, ( 2.8-10.8)] was the most significant determinant of
bleeding. The bleeding-free survival at one year was significantly differ-
ent in type 3 (52%) versus types 1 (96%) and 2 (91%) VWD. On the oth-
er hands, patients with VWF.RCo >30 U/dL and FVIII:C > 40 U/dL
showed always BSS <5 with the lowest incidence of bleeding (5.0×100
patient-years). A total of 292 DDAVP injections were used to manage
bleeding and surgeries in types 1 (65%) and 2 (35%) VWD and 452 injec-
tions of VWF concentrates were used to treat bleeding and surgeries in
type 3 (75%), type 2 (34%) and type 1 (15%) VWD. Conclusions. Based
on the results of this prospective study, we can confirm that BSS is an
important clue to predict clinical bleeding and the need of therapy with
DDAVP and VWF concentrates. In cases with VWF.RCo >30 U/dL and
FVIII:C >40 U/dL bleedings occurs very rarely in agreement with their
relatively low BSS. 
CO-059
AME AFFECTS MGAKARYOCYTIC DIFFERENTIATION AND INCREASES PRO-PLATELATS
FORMATION IN VITRO
Rinaldi CR,1 Senyuk V,2 Laricchia-Robbio L,2 Yanamandra S,2 Pane F,1
Rotoli B,1 Nucifora G2
1Cattedra di Ematologia, Università Federico II, Napoli, Italy; 2University of Illi-
nois in Chicago (UIC), Department of Medicine, Section Hematology-Oncolo-
gy, Chicago, IL, USA
The t(3;21)(q26;q22) resulting in the AML1/MDS1/EVI1 (AME) fusion
gene is associated with several hematological disorders often character-
ized by severe dysmegakaryopoiesis, suggesting that AME alters the
megakaryocytic maturation program. We expressed the AME fusion
protein in bone marrow lineage negative cells by retroviral infection.
The cells were cultured in presence of TPO to induce megakaryocytic
differentiation and on day 2 the morphology was analyzed after Wright
Giemsa staining. In the AME positive cultures we counted a 5 fold
increase (35%) of MKs percentage compared with the control cells (7%).
AME positive MKs were smaller in size in comparison to the control. In
AME cultures we frequently observed micro-megakaryocytes and oth-
er features of dismegakaryopoiesis. During 12 days in liquid culture in
presence of TPO, while the control MKs persisted for the entire exper-
iment, the AME positive MKs quickly decreased after 7 days. AME pos-
itive MKs produced platelets until day 6. The platelets appeared imma-
ture, bigger in size with several features of pro-platelets. The AME
platelets were found 10 fold increased as compared to controls and their
formation was prolonged for more than 7 days while the control MKs
produced platelets for only 2 days. We also expressed AME in the human
erythromyeloblastoid cell line K562. PMA was used to induce megakary-
ocytic differentiation. The cells were collected after 48 and 96 hours and
then compared with the control differentiated K562. The DNA content
was measured after propidium iodinate (PI) staining by FACS analysis.
AME-K562 showed a block in megakaryocytic differentiation. As pre-
viously demonstrated in murine cells, also AME-differentiated-K562
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